Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Michael Untch"'
Autor:
Guilherme Nader-Marta, Véronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen I. Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja
Publikováno v:
British journal of cancer. 127(10)
Patients with small node-negative HER2-positive breast cancer are commonly treated with paclitaxel and 1 year of adjuvant trastuzumab. We performed a sub-analysis of the ALTTO trial to explore the long-term outcomes of patients with small node-negati
Autor:
Frederik Marmé, Hans-Joachim Lück, Ralph Wirtz, Isabell Witzel, Carsten Denkert, Michael Untch, Karsten Weber, Christian Schem, Jens Huober, Peter A. Fasching, Volkmar Müller, Thomas Karn, Marion von Mackelenbergh, Sibylle Loibl, Elmar Stickeler
Publikováno v:
British Journal of Cancer
British journal of cancer : BJC 121(12), 1009-1015 (2019). doi:10.1038/s41416-019-0630-3
British journal of cancer : BJC 121(12), 1009-1015 (2019). doi:10.1038/s41416-019-0630-3
British journal of cancer : BJC 121(12), 1009-1015 (2019). doi:10.1038/s41416-019-0630-3
Published by Nature Publ. Group, Edinburgh
Published by Nature Publ. Group, Edinburgh
Autor:
S. Loibl, Joyce Bischoff, Thomas Karn, Yasmin Issa-Nummer, Christian Schem, I. Meinhold-Heerlein, Maik Hauschild, Brigitte Rack, Volkmar Müller, C. zu Eulenburg, Michael Untch, F Khandan, H. Eidtmann, Peter A. Fasching, Sabine Schmatloch, J Huober, Christine Mau, Cornelia Liedtke, G. von Minckwitz, Tanja Fehm, Isabell Witzel
Publikováno v:
British Journal of Cancer
Background: We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is stil
Autor:
V Georgoulias, J. Gasmi, M Pawlicki, P Kellokumpu-Lehtinen, Lubos Petruzelka, A Chan, V Guillem-Porta, T Bourlard, M. Z. Wojtukiewicz, Michael Untch, G. Villanova, Miguel Gil, H L Sommer, Miguel Martín, N Battelli, D. Aubert
Publikováno v:
British Journal of Cancer
The aim of this international phase II trial was to determine the efficacy and safety profile of weekly vinorelbine plus trastuzumab as first-line chemotherapy for women with HER 2-overexpressing metastatic breast cancer. Sixty-nine patients with tum
Publikováno v:
British Journal of Cancer
We examined bone marrow aspirates from 100 metastasis-free primary breast cancer patients. In 38/100 patients (38%), tumour cells were detected in the marrow using an immunocytochemical technique with a cocktail of two monoclonal antibodies: anti-EMA
Autor:
M. Schwaiger, Michael Untch, C Weber, S Avril-Sassen, Sven Mahner, Norbert Avril, Fritz Jänicke, Annette Lebeau, Reinhold Tiling, J Dose-Schwarz
Publikováno v:
British Journal of Cancer
Background: The aim of this was to evaluate FDG-PET (2-(fluorine-18)-fluoro-2-deoxy-D-glucose positron emission tomography) for assessment of residual tumour after primary chemotherapy of large and locally advanced breast cancer in comparison with co
Publikováno v:
British Journal of Cancer
Decision aids in North American breast cancer outpatients have been shown to assist with treatment decision making and reduce decisional conflict. To date, appropriate delivery formats to effectively increase patient participation in newly diagnosed
Autor:
A. Fateh-Moghadam, G E Konecny, Michael Untch, F G Ebeling, Dorothea Nagel, Dietrich Seidel, U M Schmitt, Petra Stieber
Publikováno v:
British Journal of Cancer
In the present study, we investigated the association of the serum levels of the tumour markers carcinoembryonic antigen and cancer antigen 15-3 with disease free survival and death from disease in 1046 women with breast cancer without metastases at